Globus Medical Stock News

Upgrades According to Morgan Stanley, the prior rating for Bank of New York Mellon Corp (NYSE:BK) was changed from Underweight to Equal-Weight. In the fourth quarter, Bank of New York Mellon showed an

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Las Vegas, USA, March 08, 2022 (GLOBE NEWSWIRE) -- Surgical Robotic Systems Market to Grow at a Significant CAGR of 11.5% by 2026, as per DelveInsight''s Analysis The demand for Surgical Robotic Systems is witnessing a huge surge due to increasing surgical procedures which can be attributed to various factors such as increasing geriatric population who form a big part of the at-risk population for prostate cancer, valvular diseases, endometriosis among other diseases leading to a direct increase in the Surgical Robotic Systems Market. DelveInsight''s Surgical Robotic Systems Market Insights and Forecast report provides the current and forecast Surgical Robotic Systems Market, upcoming innovation in the devices, individual market shares, challenges, drivers, and barriers, market trends, and key competitors in the Surgical Robotic Systems Market. Some of the essential factors from the Surgical Robotic Systems Market report: As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth and occupy the largest Surgical Robots market share.

Globus Medical (GMED) expands share repurchase program by authorizing the repurchase of an additional $200M worth stock

AUDUBON, Pa., March 04, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has expanded the Company�

Globus has continued to gain share in the U.S. spine market, helping to drive a decent Q4'21 revenue beat while robotics-related demand remains strong.

Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO) said the U.S. Food and Drug

Globus Medical Inc''s (NYSE: GMED ) Q4 sales reached $250 million, +7.1% Y/Y (up 7.4% on a constant currency basis), beating the consensus of $243.52 million. The U.S. net sales, including robotics, increased by 7.2% to $212.96 million. International net sales increased by 6.8% and 8.7% on a constant currency basis, to $37.06 million. Sales from Musculoskeletal … Full story available on Benzinga.com

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

GMED earnings call for the period ending December 31, 2021.